EP 1307229 A1 20030507 - COMBINATION PREPARATION WITH AN ER-BETA SELECTIVE ESTROGEN AND A SERM
Title (en)
COMBINATION PREPARATION WITH AN ER-BETA SELECTIVE ESTROGEN AND A SERM
Title (de)
KOMBINATIONSPRÄPARATE AUS EINEM ER-BETA-SELEKTIVEN ESTROGEN UND EINEM SERM
Title (fr)
PREPARATIONS COMBINEES CONSTITUEES D'UN OESTROGENE SELECTIF DE L'ER-BETA ET D'UN SERM
Publication
Application
Priority
- DE 10039199 A 20000810
- EP 0109008 W 20010803
Abstract (en)
[origin: WO0211765A1] A novel medicament for the treatment of estrogen-deficient disease states is disclosed. Said medicament is a combination preparation comprising an ERss-selective estrogen and an ER alpha -selective antiestrogen or SERM (Selective Estrogen Receptor Modulator). The antiestrogen or SERM which is a component of the combination preparation is preferably selective for the periphery. The preparation is suitable for an organ-specific estrogen therapy and has clear advantages over conventional therapies. Due to the combination of ER alpha -selective SERM and ERss-estrogen the preparation permits a complete protection against bone loss caused by estrogen deficiency. The components of the medicament also have a synergistic effect with respect to the inhibition of inflammation inducing genes, in particular in inflammatory disorders such as atherosclerosis and arthritis, or neurodegenerative diseases such as Alzheimers and multiple sclerosis. Furthermore, positive effects on cognition and mood may be expected. The protective estrogen-like effects are achieved, with no expectation of proliferation effects on breasts or uterus.
IPC 1-7
IPC 8 full level
A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 31/00 (2006.01); A61K 31/56 (2006.01); A61K 31/565 (2006.01); A61P 5/00 (2006.01); A61P 5/24 (2006.01); A61P 5/30 (2006.01); A61P 5/32 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 13/08 (2006.01); A61P 15/12 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); A61P 25/20 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP US)
A61K 31/00 (2013.01 - EP US); A61K 31/565 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 5/00 (2017.12 - EP); A61P 5/24 (2017.12 - EP); A61P 5/30 (2017.12 - EP); A61P 5/32 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 13/08 (2017.12 - EP); A61P 15/12 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 0211765A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated extension state (EPC)
LT LV RO SI
DOCDB simple family (publication)
WO 0211765 A1 20020214; AU 9372001 A 20020218; DE 10039199 A1 20020221; EP 1307229 A1 20030507; JP 2004505929 A 20040226; US 2004053898 A1 20040318
DOCDB simple family (application)
EP 0109008 W 20010803; AU 9372001 A 20010803; DE 10039199 A 20000810; EP 01974107 A 20010803; JP 2002517099 A 20010803; US 34416103 A 20030926